{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:04:09Z","timestamp":1781859849852,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1038\/sj.bjc.6600272","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:17:46Z","timestamp":1031249866000},"page":"1555-1560","source":"Crossref","is-referenced-by-count":33,"title":["Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours"],"prefix":"10.1038","volume":"86","author":[{"given":"K","family":"Fizazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D M","family":"Prow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K-A","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Daliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C N","family":"Papandreou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S-M","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Millikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L C","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,5,20]]},"reference":[{"key":"BF6600272_CR1","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0959-8049(00)00137-4","volume":"36","author":"F Andr\u00e9","year":"2000","unstructured":"Andr\u00e9 F, Fizazi K, Culine S, Droz JP, Taupin P, Lhomme C, Terrier-Lacombe M, Th\u00e9odore C (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of a rare complication of non seminomatous germ-cell tumors. Eur J Cancer 36: 1389\u20131394","journal-title":"Eur J Cancer"},{"key":"BF6600272_CR2","first-page":"169","volume":"77","author":"D Baume","year":"1990","unstructured":"Baume D, Pico JL, Droz JP, Ostronoff M, Azab M, Gilles E, Ghosn M, Salloum E, Gouyette A, Beaujean F (1990) Value of high-dose chemotherapy followed by bone marrow autograft in non-seminomatous germinal tumor with poor prognosis. Results of the combination of cisplatinum, etoposide and cyclophosphamide. Bull Cancer 77: 169\u2013180","journal-title":"Bull Cancer"},{"key":"BF6600272_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.1995.13.1.283","volume":"13","author":"C Bokemeyer","year":"1995","unstructured":"Bokemeyer C, Schmoll HJ (1995) Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13: 283\u2013292","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR4","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1200\/JCO.1999.17.11.3450","volume":"17","author":"C Bokemeyer","year":"1999","unstructured":"Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C (1999) First-line high-dose chemotherapy compared with standard-dose PEB\/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 17: 3450\u20133456","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJM199707243370406","volume":"337","author":"GJ Bosl","year":"1997","unstructured":"Bosl GJ, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337: 242\u2013253","journal-title":"N Engl J Med"},{"key":"BF6600272_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1023\/A:1008279222625","volume":"8","author":"M Bower","year":"1997","unstructured":"Bower M, Newlands ES, Holden L, Rustin GJ, Gegent RH (1997) Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB\/ACE chemotherapy. Ann Oncol 8: 477\u2013483","journal-title":"Ann Oncol"},{"key":"BF6600272_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000474596","volume":"23","author":"C Chevreau","year":"1993","unstructured":"Chevreau C, Droz JP, Pico JL, Biron P, Kerbrat P, Cure H, Heron JF, Chevallier B, Fargeot P, Kramar A (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 23: 213\u2013217","journal-title":"Eur Urol"},{"key":"BF6600272_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/1040-8428(96)00196-5","volume":"22","author":"S Culine","year":"1996","unstructured":"Culine S, Kramar A, Biron P, Droz JP (1996) Chemotherapy in adult germ cell tumors. Crit Rev Oncol Hematol 22: 229\u2013263","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF6600272_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/JCO.1998.16.2.799","volume":"16","author":"E Cvitkovic","year":"1998","unstructured":"Cvitkovic E (1998) Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity. J Clin Oncol 16: 799\u2013800","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/bjc.1998.587","volume":"78","author":"R de Wit","year":"1998","unstructured":"de Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Pricjck L, Collette L, Sylvester R (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78: 828\u2013832","journal-title":"Br J Cancer"},{"key":"BF6600272_CR11","first-page":"173a","volume":"20","author":"JP Droz","year":"2001","unstructured":"Droz JP, Culine S, Bouzy J, Th\u00e9odore C, Geoffrois L, Biron P, Bui B, Peny J, Kerbrat P, Chevreau C, Delva R, Fargeot P, Platini C, Fizazi K, Caty A, Kramar A (2001) Preliminary results of a randomized trial comparing bleomycin, etoposide, cisplatin (BEP) and cyclophosphamide, doxorubicin, cisplatin\/ vinblastine, bleomycin (CISCA\/VB) for patients (pts) with intermediate- and poor-risk metastatic non seminomatous germ-cell tumors (NSGCT). Proc Am Soc Clin Oncol 20: 173a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600272_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1200\/JCO.1998.16.2.725","volume":"16","author":"K Fizazi","year":"1998","unstructured":"Fizazi K, Culine S, Droz JP, Kramar A, Theodore C, Ruffie P, Le Chevalier T (1998) Primary mediastinal non-seminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol 16: 725\u2013732","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1023\/A:1008344014518","volume":"11","author":"K Fizazi","year":"2000","unstructured":"Fizazi K, Zelek L (2000) One cycle every 3 or 4 weeks: is it obsolete? A review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 11: 133\u2013149","journal-title":"Ann Oncol"},{"key":"BF6600272_CR14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/1097-0142(20010915)92:6<1460::AID-CNCR1470>3.0.CO;2-I","volume":"92","author":"K Fizazi","year":"2001","unstructured":"Fizazi K, Amato RJ, Beuzeboc P, Petit N, Bouhour D, Thyss A, Rebischung C, Chevreau C, Logothetis CJ, Droz JP (2001) Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer 92: 1460\u20131467","journal-title":"Cancer"},{"key":"BF6600272_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/annonc\/mdf005","volume":"13","author":"K Fizazi","year":"2002","unstructured":"Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ (2002) A 20% dose reduction of the original CISCA\/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: Final results of a phase III randomized trial. Ann Oncol 13: 125\u2013134","journal-title":"Ann Oncol"},{"key":"BF6600272_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000474859","volume":"21","author":"JR Germa Lluch","year":"1992","unstructured":"Germa Lluch JR, Segui Palmer MA, Climent Duran MA, Blanco-Guerrero R, Fernandez Sagarra A, Villaviciencio H, Sole Balcells FJ (1992) Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis. Eur Urol 21: 287\u2013293","journal-title":"Eur Urol"},{"key":"BF6600272_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1023\/A:1008351022211","volume":"10","author":"JR Germa-Lluch","year":"1999","unstructured":"Germa-Lluch JR, Garcia del Muro X, Tabernero JM, Sanchez M, Aparicio J, Alba E, Barnabas A (1999) BOMP\/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience. Ann Oncol 10: 289\u2013293","journal-title":"Ann Oncol"},{"key":"BF6600272_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/oxfordjournals.annonc.a057904","volume":"2","author":"A Harstrick","year":"1991","unstructured":"Harstrick A, Schmoll HJ, Kohne-Wompner CH, Bergmann L, Lammers U, Hohnloser J, Dolken G, Reichhardt P, Siegert W, Natt F (1991) Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol 2: 197\u2013202","journal-title":"Ann Oncol"},{"key":"BF6600272_CR19","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J","volume":"39","author":"DM Hayes","year":"1977","unstructured":"Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine dichloride. Cancer 39: 1372\u20131381","journal-title":"Cancer"},{"key":"BF6600272_CR20","first-page":"341a","volume":"19","author":"SW Hinton","year":"2000","unstructured":"Hinton SW, Catalano PJ, Einhorn LW, Nichols CR, Crawford ED, Vogelzang NJ, Trump DL, Loehrer PJ (2000) Re-analysis of the intergroup trial (E3887) of cisplatin and etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors using the International Germ Cell Consensus Classification. Proc Am Soc Clin Oncol 19: 341a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600272_CR21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/0959-8049(94)00329-4","volume":"30A","author":"A Horwich","year":"1994","unstructured":"Horwich A, Dearnaley DP, Norman A, Nicholls J, Hendry WF (1994) Accelerated chemotherapy for poor prognosis germ-cell tumours. Eur J Cancer 30A: 1607\u20131611","journal-title":"Eur J Cancer"},{"key":"BF6600272_CR22","first-page":"319a","volume":"16","author":"A Horwich","year":"1997","unstructured":"Horwich A, Mason M, Fossa SD, Mead GM, Huddart R, Nicholls J, Norman A, Dearnaley DP (1997) Accelerated induction chemotherapy (C-BOP-BEP) for poor and intermediate prognosis metastatic germ-cell tumours (GCT). Proc Am Soc Clin Oncol 16: 319a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600272_CR23","doi-asserted-by":"crossref","unstructured":"International Germ Cell Consensus Classification (1997) A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594\u2013603","DOI":"10.1200\/JCO.1997.15.2.594"},{"key":"BF6600272_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.1998.16.2.692","volume":"16","author":"SB Kaye","year":"1998","unstructured":"Kaye SB, Mead GM, Fossa S, Cullen M, de Wit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemend E, deMulder P (1998) Intensive induction-sequential chemotherapy with BOP\/VIP-B compared with treatment with BEP\/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council\/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16: 692\u2013701","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1023\/A:1008333229936","volume":"11","author":"C Kollmannsberger","year":"2000","unstructured":"Kollmannsberger C, Nichols C, Meisner C, Mayer F, Kanz L, Bokemeyer C (2000) Identification of prognostic subgroups among patients with metastatic \u2018IGCCCG poor-prognosis\u2019 germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol 11: 1115\u20131120","journal-title":"Ann Oncol"},{"key":"BF6600272_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/oxfordjournals.annonc.a057906","volume":"2","author":"CR Lewis","year":"1991","unstructured":"Lewis CR, Fossa SD, Mead G, ten Bokkel Huinink W, Harding MJ, Mill L, Paul J, Jones WG, Rodenburg CJ, Cantwell B (1991) BOP\/VIP \u2013 A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 2: 203\u2013211","journal-title":"Ann Oncol"},{"key":"BF6600272_CR27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/1097-0142(19821015)50:8<1629::AID-CNCR2820500828>3.0.CO;2-1","volume":"50","author":"CJ Logothetis","year":"1982","unstructured":"Logothetis CJ, Samuels ML, Trindade A, Johnson DE (1982) The growing teratoma syndrome. Cancer 50: 1629\u20131635","journal-title":"Cancer"},{"key":"BF6600272_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.1985.3.3.326","volume":"3","author":"CJ Logothetis","year":"1985","unstructured":"Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC (1985) Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 3: 326\u2013335","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0002-9343(86)90255-X","volume":"81","author":"CJ Logothetis","year":"1986","unstructured":"Logothetis CJ, Samuels ML, Selig DE, Ogden S, Dexeus F, Swanson D, Johnson D, von Eschenbach (1986) A Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results in 100 patients. Am J Med 81: 219\u2013228","journal-title":"Am J Med"},{"key":"BF6600272_CR30","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2001.19.9.2534","volume":"19","author":"M Mazumdar","year":"2001","unstructured":"Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19: 2534\u20132541","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR31","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JCO.1991.9.7.1163","volume":"9","author":"CR Nichols","year":"1991","unstructured":"Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163\u20131172","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1200\/JCO.1998.16.4.1287","volume":"16","author":"CR Nichols","year":"1998","unstructured":"Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16: 1287\u20131293","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.1988.6.6.1031","volume":"6","author":"RF Ozols","year":"1988","unstructured":"Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC (1988) A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031\u20131040","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/1097-0142(19840301)53:5<1029::AID-CNCR2820530503>3.0.CO;2-Z","volume":"53","author":"MK Samson","year":"1984","unstructured":"Samson MK, Rivkin SE, Jones SE, Costanzi JJ, LoBuglio AF, Stephens RL, Gehan EA, Cummings GD (1984) Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 53: 1029\u20131035","journal-title":"Cancer"},{"key":"BF6600272_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1\u201310","journal-title":"Control Clin Trials"},{"key":"BF6600272_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1200\/JCO.1995.13.1.87","volume":"13","author":"MJ Stevens","year":"1995","unstructured":"Stevens MJ, Norman AR, Dearnaley DP, Horwitch A (1995) Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 13: 87\u201392","journal-title":"J Clin Oncol"},{"key":"BF6600272_CR37","first-page":"5904","volume":"50","author":"GC Toner","year":"1990","unstructured":"Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ (1990) Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50: 5904\u20135910","journal-title":"Cancer Res"},{"key":"BF6600272_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/1097-0142(19840115)53:2<203::AID-CNCR2820530203>3.0.CO;2-U","volume":"53","author":"JN Wettlaufer","year":"1984","unstructured":"Wettlaufer JN, Feiner AS, Robinson WA (1984) Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors. Cancer 53: 203\u2013209","journal-title":"Cancer"},{"key":"BF6600272_CR39","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJM198706043162302","volume":"316","author":"SD Williams","year":"1987","unstructured":"Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435\u20131440","journal-title":"N Engl J Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6600272","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:42:30Z","timestamp":1684413750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6600272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["BF6600272"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6600272","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}